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Machine Learning in radiation 
Oncology: Opportunities, 
requirements, and Needs
Mary Feng*, Gilmer Valdes, Nayha Dixit and Timothy D. Solberg
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, United States
Machine learning (ML) has the potential to revolutionize the field of radiation oncology, 
but there is much work to be done. In this article, we approach the radiotherapy process 
from a workflow perspective, identifying specific areas where a data-centric approach 
using ML could improve the quality and efficiency of patient care. We highlight areas 
where ML has already been used, and identify areas where we should invest additional 
resources. We believe that this article can serve as a guide for both clinicians and 
researchers to start discussing issues that must be addressed in a timely manner.
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iNtrODUctiON
The expanding collection and sharing of data, increases in computational power, and perhaps most 
significantly, advances in machine learning (ML) and artificial intelligence, are rapidly transforming 
society, and offer the potential for similar transformation within health care. Ongoing advances in 
ML and big data analytics have spurred numerous efforts in precision oncology (1, 2), and the field 
of radiation oncology is uniquely poised to benefit from prudent application of such techniques. 
Radiation oncology has many specific challenges, however, ranging from unique datasets [e.g., 4DCT, 
CBCT, dose, structures, setup, and quality assurance (QA) information], limited clinical outcomes 
data, variation in dose and fraction schedules comprising standard of care, interaction of radiation 
and chemotherapy, limited access to genomics data, and other complexities. The historical reliance 
on empirical approaches such as the linear-quadratic model further influences clinical practice (3). 
Furthermore, the current ML hype is largely a result of success in a few, very specific tasks, such as 
image classifications, games, and autonomous driving systems (4–6). It is critical that we understand 
this success depends as much on the nature of the task as on the nature of the algorithm and the 
availability and quality of data, and thus meaningful gains in our field may prove more challenging.
In this article, we review the radiotherapy process from a workflow perspective, identifying 
specific areas where ML could improve the quality and efficiency of the current caregiving process 
for patients treated with radiation therapy. We have divided radiotherapy into six serial stages that 
encompass the entirety of treatment: patient assessment, simulation, planning, QA, treatment deliv-
ery, and follow-up, Figure 1. In each of these areas, we have identified open questions, emerging 
techniques, and possible directions concerning all stakeholders: patients, oncologists, physicists, 
dosimetrists, therapists, and nurses. Each stage is accompanied by a systematic assessment of oppor-
tunities, expectations, applicability, and limitations of various ML algorithms. While the impact a 
data-centric approach can have on improving the quality of treatment for cancer patients is clear, 
utilizing such a method will require a cultural shift at both the professional and institutional levels. 
We believe that this article will serve as a guide for both clinicians and researchers on those problems 
that must be addressed in a timely manner.
FigUre 1 | Radiotherapy workflow, from consult to follow-up.
2
Feng et al. ML in Radiation Oncology
Frontiers in Oncology | www.frontiersin.org April 2018 | Volume 8 | Article 110
PAtieNt AssessMeNt
The radiation oncology process begins at the first consultation. 
During this time, the radiation oncologist and patient meet to 
discuss the clinical situation, including the risks and benefits of 
treatment and the patient’s goals of care, to determine a treatment 
strategy. Useful information to assess the potential benefit of treat-
ment includes tumor stage, mutational status or gene signatures 
(e.g., MGMT, Oncotype score), viral status (e.g., HPV), prior 
and current therapies, margin status if post-resection, ability to 
tolerate multimodality therapy, and overall performance status. 
Balanced with this are parameters that impact potential risk and 
tolerability of treatment including age, comorbidities, functional 
status, functioning of important organs, proximity between tumor 
and critical normal tissues, supportive care network, and ability 
to cooperate with motion management. All of these are features 
can be used to build predictive models of treatment outcome and 
toxicity. These models, then, can be used to inform physicians and 
patients to manage expectations and guide trade-offs between 
risks and benefit.
Having an ontology to identify and categorize the informa-
tion available at this stage is important for any successful appli- 
cation of any predictive model (7). By contrast, current predictive 
models utilizing tumor control or normal tissue complication 
probability are neither subdivided nor categorized according to 
current state of a patient within the treatment timeline (8–12). 
Rather, they make use of a predetermined set of features, col-
lected by individual investigators, that may have previously 
shown correlation to a particular clinical outcome (8–12). 
As a result, physicians are limited by scare and siloed data, 
making it often necessary to make informed guesses rather than 
data-driven decisions.
Many opportunities can be found for predictive models at the 
stage of initial consult. Here are a few practical examples in which 
a data-centric approach could improve decision making at the 
time of consultation:
 (1) You are asked to see an inpatient who has a painful cervical 
spine metastasis. She will be discharged to hospice. What 
information may be helpful to determine whether to recom-
mend RT? On one hand, radiotherapy can palliate her pain. 
However, she may not live long enough to benefit from treat-
ment, but will have the discomfort associated with transfers 
and positioning for simulation/treatment, acute esophagitis, 
and pain flare. Narcotic management may be best for her, 
but how would we know? Models which predict time to 
pain relief, risk of toxicity, and overall survival would help 
optimize decision making at end-of-life, maximizing quality 
of life for the patient, and delivering high-value care (13).
 (2) A patient with intermediate-risk prostate cancer is referred 
to discuss therapy. Treatment options for could include 
fractionated external beam radiotherapy, stereotactic body 
radiotherapy, brachytherapy, surgery, and other non-radia-
tion approaches, without or without androgen-deprivation 
therapies. Shared decision making is crucial in this situation, 
since each type of therapy has inherent trade-offs with dif-
ferent side-effect profiles, which drives choice of therapy. 
A clinical support tool showing the balance between efficacy 
and side effects based on pre-treatment function and choice 
of therapy would be helpful for physicians and patients in 
shared decision making.
 (3) A patient with hepatitis C cirrhosis and a single hepatocel-
lular carcinoma is referred to consider treatment options. 
To determine whether to recommend SBRT over other 
treatments such as radiofrequency ablation or transarterial 
chemoembolization, information on liver function, suit-
ability for anesthesia, and proximity to bowel, heart, gall 
bladder, central biliary tree is needed. Comprehensive ways 
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to integrate tumor control and toxicity predictions from all 
treatment modalities would help the physician and patient 
to manage expectations and decide on a course of therapy. 
Within radiation oncology, there has been some work done 
to model individual radiation sensitivity to individualize and 
adapt therapy, though there is still much opportunity for 
richer predictive modeling using ML (14).
 (4) A patient with early stage left-sided breast cancer had a 
lumpectomy with negative margins and comes to discuss 
adjuvant radiotherapy. How would you decide whether she 
would benefit from deep inspiration breath-hold or inten-
sity-modulated radiotherapy rather than 3D conformal 
RT? Would proton therapy be beneficial for this patient? 
Since the complexity and cost is higher with more advanced 
technology, models to predict who would benefit would be 
helpful for technology selection and resource allocation 
(11, 15–18).
The delivery of models that could help with these scenarios 
will require a cultural shift in our profession toward standardiza-
tion and collaboration. In this regard, new collaborative projects 
have begun in recent years, though participation is not yet 
widespread (12, 19, 20). In addition, while recently published task 
reports have aimed to standardize nomenclature in radiotherapy 
(21), it is equally important to develop standards for data col-
lection. Due in part to the small datasets typically encountered 
in radiotherapy, the choice of algorithm in a specific application 
can produce differences of up to 32% in predicted outcome (22). 
It is also important to understand the goal of any modeling effort. 
If the goal is to assist physicians and patients reach the best 
decision, then a balance between interpretability of the results 
and accurate predictions is needed (23, 24). In this case, logistic 
regressions or decision trees are equally effective (23, 24). If 
accuracy is favored over interpretability, then tree base methods 
such as random forests or gradient boosting, and Support Vector 
Machines with kernel methods, consistently win most modeling 
competitions when structured data are analyzed (such as the type 
of data described above) (25, 26).
siMULAtiON
Once a physician and patient have decided to proceed with 
radiation therapy, the physician will place robust instructions for 
a Simulation, which is then scheduled. The order for simulation 
includes details about immobilization, scan range, treatment site, 
and other specifics necessary to complete the procedure appro-
priately. Patient preparation for simulation could include fiducial 
placement, fasting or bladder/rectal filling instructions, or kidney 
function testing for IV contrast. Special instructions are given for 
patients with a cardiac device or who are pregnant, and lift help 
or a translator is requested if necessary.
In most cases, a Simulation is scheduled after appropriate 
CT orders have been placed in the electronic medical record. 
Following completion and review of the CT simulation, the scan 
is exported to a planning system for the physician to contour 
tumor volumes and organs at risk (OARs). Sometimes a MR, 
PET and/or pre-operative scan is registered. With the OARs and 
tumor volumes contoured, the dosimetrists then begin designing 
a treatment plan based on specific physician instructions.
A good CT simulation is critical to the success of all subsequent 
processes, to achieve an accurate, high quality, robust, and deliver-
able plan for a patient. It is not uncommon that deficiencies at the 
time of CT simulation result in a need for a patient to return for a 
repeat CT, including insufficient scan range, incorrect IV contrast 
protocols, suboptimal immobilization, incorrect bladder/rectal 
filling, artifacts from internal hardware or those caused by the 
4DCT process, lack of breath-hold reproducibility, and so on. 
Thus, focusing on the simulation, in particular, there are many 
questions that could be answered through ML algorithms to aid 
in decision making and overall workflow efficiency:
 1. Will this patient benefit from IV contrast?
 2. Will this patient be compliant with immobilization and 
motion management technique (e.g., compression or breath 
hold)?
 3. Considering breathing patterns and other issues, will a 
4DCT be beneficial for this patient?
 4. Will this patient be able to tolerate the duration of the intended 
treatment (AP/PA vs. SBRT) and IGRT method (CBCT vs. 
kV-kV Orthogonal)?
 5. Will this patient’s anatomy allow for standard immobilization 
for simulation and treatment?
Simulation is an area where the community has focused lit-
tle effort on ML, with early work confined to predicting tumor 
motion (27–30). Additional emphasis, from both academic 
institutions and industry, can be expected in the future.
treAtMeNt PLANNiNg
The planning process starts by delineating both the target(s) and 
the OARs. While a number of commercial auto-segmentation 
algorithms exist, the underlying technology relies on an atlas-
based strategy rather than utilizing ML. The performance of 
atlas-based segmentation tools depend highly on the type 
of structure, showing better results for high-contrast organs 
(e.g., lung) while struggling with soft tissue organs (e.g., pancreas) 
(31). By contrast, recent advances in computer vision, specifically 
around deep learning (6, 32), are particularly well suited for 
auto-segmentation (33–35). In deep learning, the algorithm is 
tasked to design the best features (higher order features) from 
the raw data as well to produce the classifiers (6). This is par-
ticularly important when human experts are unable to design 
proper features or quantify a given process, as in computer 
vision problems. An important limitation of the application of 
deep learning to segmentation is the limited size of the datasets 
available in radiation oncology. Because the algorithm is tasked 
to find the features as well as the classifier, deep learning models 
contain millions of parameters, and thus require more data than 
traditional ML algorithms. In applications in which deep learn-
ing has been successfully applied, the models have been trained 
with tens of thousands observations (4, 36). Although there are 
techniques to prevent overfitting when the number of parameters 
is larger than the number of observation points (transfer learning, 
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dropout, early stopping), it remains to be demonstrated whether 
these algorithms can generalize to datasets on the order of a few 
hundred in size, even when the techniques mentioned above are 
used. In our opinion, the effective application of deep learning to 
segmentation requires training and validation on datasets across 
multiple institutions and multiple scanners.
Once the target volumes and OARs have been delineated, 
the planning process continues by (1) setting dosimetric goals 
for targets and normal tissues; (2) selecting an appropriate treat-
ment technique (e.g., 3D, fixed beam IMRT, VMAT, protons); (3) 
iteratively modifying the beams/weights/etc., until the planning 
goals have been achieved; (4) evaluating and approving the plan. 
It is in this last step where most ML applications have been 
focused (37–43). While there techniques are typically referred to 
as knowledge-based planning (KBP), it is important to highlight 
that both current academic research and available commercial 
products are limited to predicting dose–volume histograms 
(DVHs) within accepted ranges. Several authors have shown the 
value that DVH prediction has in improving population based 
treatment plan quality and in the detection of outliers (44–47).
Similar gains in steps 1–3 highlighted above would be equally 
important. For example, while KBP can predict DVHs, the intrin-
sic trade-offs between dosimetric indices that must be considered 
in step 1 are not currently predicted. A more recent commercial 
product, Quick Match (Siris Medical, Redwood City, CA, USA), 
uses gradient boosting (the most accurate algorithm on expecta-
tion when structured data are available) to explore predictions in 
dosimetric trade-offs (17). This application, which is similar to a 
treatment planning Pareto solution but obtained before the treat-
ment planning process, can facilitate communication between 
dosimetrist and physicians, establish individualized and achiev-
able goals, and help physicians and patients decide the course 
of plan before embarking on the treatment planning process. 
In addition, by allowing the exploration of intrinsic trade-offs, 
it can also help to choose an optimal technique (e.g., photon vs. 
protons).
Once the dosimetric goals have been established and the 
technique chosen, automatic plan generation is also possible. 
Attempts have been made to solve various aspects of this prob-
lem, for instance, predicting the best beam orientations (48, 49). 
The larger task of automated treatment planning, however, is well 
suited for reinforcement learning. In this technique, widely used 
in games, self-driving cars, and other popular-culture applica-
tions, an algorithm learns to navigate a set of rules, given some 
constraints, by self-correcting its decisions. For example, one 
could use fundamental laws of radiation interaction to achieve 
certain dosimetric constraints. Essentially, the algorithm will take 
a decision (for instance, increase the weight of a given constraint) 
and learn from the simulator (the treatment planning system) 
whether the decision resulted in the right direction. Common 
to successful applications of reinforcement learning is the ability 
to generate synthetic data using a simulator (e.g., games). This 
technique, successfully used by Google Brain to develop an algo-
rithm capable of beating a Go world champion (5), could provide 
performance at the level of our best dosimetrists if properly 
implemented. One challenge of achieving automatic planning 
using reinforcement learning lies in the close integration that 
this research endeavor will need with robust treatment planning 
systems. Therefore, it seems likely that an industry/academic 
partnership is best suited to achieve this goal. Summarizing then, 
in the future, we envision the planning process to happen fully 
automatically, from contouring to plan creation, with the human 
experts (dosimetrists, physicists, and physicians) evaluating, 
supervising, and providing QA to the given results.
QA AND treAtMeNt DeLiverY
A number of aspects of a radiotherapy QA program, specifically 
in error detection and prevention, treatment machine QA, and 
time series analyses, are well suited to the application of ML 
(50–53). Li and Chan developed an application to predict the 
performance of linear accelerators over time (51). Valdes et  al. 
developed ML applications to predict IMRT QA passing rates 
(52, 53) and to automatically detect problems with the Linac 
imaging system (50). Carlson et  al. developed a ML approach 
to predict multi-leaf collimator positional errors (54). El Naqa 
developed system to detect anomalies in QA data (55). Finally, 
Ford et al. have developed a tool to quantify the value of quality 
control checks in radiation oncology (56). The ability of these 
algorithms to automatically detect outliers allows physicists to 
focus attention on those aspects of a process most likely to impact 
our patient care, as recommended in Task Group 100 (57).
Other important applications of ML include predicting plan-
ning deviations from the initial intentions and predicting the 
need for re-planning. Guidi et al. developed a ML-based tool to 
predict when head and neck patients treated with photons need 
re-planning (58). In a similar fashion, Tseng et al. used three deep 
neural networks to predict the need for treatment adaptation for 
lung patients (59, 60). Varfalvy et al. used relative gamma analysis 
and hidden Markov models to categorize patients based on dev-
iations from the initial treatment plan to identify patients in need 
of re-planning. The need to predict proton patients who would 
benefit from a re-plan is even more relevant, though no publica-
tions exist in this setting to date. Deciding on the best algorithm 
for QA applications is critical for accurately predicting outcomes. 
While it is clear that each of the applications described above are 
important and useful, all remain within the domain of research 
and have not been made available commercially.
FOLLOW-UP
Machine learning also has the potential to change the way radia-
tion oncologists follow patients treated with definitive therapy. 
Following surgery, the tumor may disappear on imaging, and 
tumor markers may quickly normalize. By contrast, the evolu-
tion of imaging changes (loss of enhancement, PET avidity, or 
diffusion restriction; stability or decrease in size) and response of 
tumor markers is gradual following radiotherapy. These features 
are monitored regularly over time, with qualitative changes 
complemented with clinical experience providing indication of 
therapeutic efficacy. Clearly, better models based on early assess-
ment are needed to predict outcome, in time for treatment inten-
sification with additional RT, early addition of systemic therapy, 
or application of a different treatment modality. In this regard, 
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early work in the area of radiomics seems promising. In radiom-
ics, quantitative features, including those based on size and shape, 
image intensity, texture, relationships between voxels, and fractal 
characteristics, are extracted to characterize an image. ML algo-
rithms can then be deployed to correlate the image-based features 
with biological observations or clinical outcomes (59–64). The 
limited reproducibility of imaging systems both within and across 
institutions remains a significant challenge for radiomics (65, 66). 
And while the application of deep learning to image quantifica-
tion has produced stellar results in other areas (67), it is important 
to understand that these techniques required thousands of data 
points even when transfer learning was used, which can prove 
challenging in radiation oncology, where datasets are limited.
cONcLUsiON
Machine learning is poised to impact the profession of radiation 
oncology, from patient consult to follow-up. While the excitement 
around ML and big data is well justified, many challenges remain, 
a number of which we have tried to describe above. There are also 
several broad challenges we will have to address as a field. The 
first is the creation and curation of large datasets. Although it is 
highly unlikely that robust models can be built with data from a 
single institution alone, the need to develop data sharing agree-
ments can be a significant barrier to the development of these 
models. One potential solution to the challenges associated with 
multi-institutional data sharing is the use of distributed learning; 
the group at Maastricht University led by Philippe Lambin has 
been pioneering this approach (68, 69). Standardization of the 
data collection process is also essential for training models using 
datasets from multiple institutions. In addition, it is important to 
highlight that distributed learning and transfer learning are part 
of the larger discipline of ML and to maximize learning from all 
centers while customizing the solution to each, mathematical guar-
antees and constraints are necessary to ensure algorithms do not 
“forget” previous seen datasets (70). Tailoring these algorithms to 
radiation oncology needs will also be an active research area in the 
future. Quality of data is also of paramount importance as no ML 
algorithm today can fix problems contained within the training 
data. In this regard, interpretability of algorithms used (e.g., ability 
for humans experts to understand reasons behind a prediction) 
will play an important role to avoid preventable errors (23).
Finally, training of our workforce and updating our educa-
tional curriculums will be increasingly important. As with any 
algorithm that we use in radiation oncology today (e.g., dose 
calculation, deformable registration), ML algorithms will need 
commissioning and QA. Clinicians will need to learn to inter-
pret and understand the limitations of any results. The field of 
radiation oncology is highly algorithmic and data-centric, and 
while the road ahead is filled with potholes, the destination holds 
tremendous promise.
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